본문으로 건너뛰기
← 뒤로

Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.

Gastroenterology 2025 Vol.169(2) p. 261-276

Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P

📝 환자 설명용 한 줄

[BACKGROUND & AIMS] Screening for, and treating, Helicobacter pylori in the general population or patients with early gastric neoplasia could reduce incidence of, and mortality from, gastric cancer.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 0.38-0.71
  • 추적기간 2 years
  • 연구 설계 meta-analysis

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ford AC, Yuan Y, et al. (2025). Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.. Gastroenterology, 169(2), 261-276. https://doi.org/10.1053/j.gastro.2024.12.033
MLA Ford AC, et al.. "Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.." Gastroenterology, vol. 169, no. 2, 2025, pp. 261-276.
PMID 39824392

Abstract

[BACKGROUND & AIMS] Screening for, and treating, Helicobacter pylori in the general population or patients with early gastric neoplasia could reduce incidence of, and mortality from, gastric cancer. We updated a meta-analysis of randomized controlled trials (RCTs) examining this issue.

[METHODS] We searched the literature through October 4, 2024, identifying studies examining effect of eradication therapy on incidence of gastric cancer in H pylori-positive adults without gastric neoplasia at baseline or H pylori-positive patients with gastric neoplasia undergoing endoscopic mucosal resection (EMR) in either RCTs or observational studies. The control arm received placebo or no eradication therapy in RCTs and no eradication therapy in observational studies. Follow-up was ≥2 years. We estimated relative risks (RR) of gastric cancer incidence and mortality.

[RESULTS] Eleven RCTs and 13 observational studies were eligible. For RCTs, RR of gastric cancer was lower with eradication therapy in healthy H pylori-positive individuals (8 RCTs, 0.64; 95% confidence interval [CI], 0.48-0.84) and H pylori-positive patients with gastric neoplasia undergoing EMR (3 RCTs, 0.52; 95% CI, 0.38-0.71). RR of death from gastric cancer was lower with eradication therapy in healthy H pylori-positive individuals (5 RCTs, 0.78; 95% CI, 0.62-0.98). In observational studies, RR of future gastric cancer was lower with eradication therapy in H pylori-positive subjects without gastric neoplasia at baseline (11 studies, 0.56; 95% CI, 0.43-0.73) and H pylori-positive patients with gastric neoplasia undergoing EMR (2 studies, 0.19; 95% CI, 0.06-0.61).

[CONCLUSIONS] This meta-analysis provides further evidence that administering eradication therapy prevents gastric cancer in H pylori-positive individuals, with consistency in results among studies of different design.

MeSH Terms

Humans; Stomach Neoplasms; Helicobacter Infections; Helicobacter pylori; Randomized Controlled Trials as Topic; Observational Studies as Topic; Anti-Bacterial Agents; Incidence; Endoscopic Mucosal Resection; Treatment Outcome; Proton Pump Inhibitors

같은 제1저자의 인용 많은 논문 (1)